Background: Levodopa-induced dyskinesia (LID) is a major complication of dopamine replacement drug usage in Parkinson's disease (PD) patients. Since the mechanism of LID is yet unclear, we analyzed serial [I-123] N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (I-123 FP-CIT) single photon emission computed tomography (SPECT) images. We investigated the changes of dopaminergic innervation during the progression of PD in relation to the development of LID.Methods: Data were obtained from the Parkinson's Progression Markers Initiative (PPMI) database. Two hundred and ninety PD dopamine replacement drug-naïve patients (age 61.0 ± 9.7, M: F = 195: 95) were enrolled. I-123 FP-CIT SPECT images from baseline, 12, 24, and 48 months wer...
The pathophysiology of levodopa-induced dyskinesias (LID) in Parkinson’s disease is not well underst...
We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocki...
Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic...
Background: In Parkinson’s disease (PD), the onset of levodopa-induced dyskinesias (LIDs) is difficu...
Levodopa-induced dyskinesias (LIDs) occur in the majority of patients with Parkinson's disease (PD) ...
The pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease is incompletely understoo...
[Purpose] To determine whether the development of levodopa-induced dyskinesia (LID) in Parkinson dis...
Objective: To investigate whether the magnitude of presynaptic dopamine depletion is a risk factor f...
We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or ab...
Levodopa-induced dyskinesia (LID), a long-term motor complication in Parkinson's disease (PD), is at...
Background and aims Serotonergic terminals play an important role in levodopa-induced dyskinesias (L...
Levodopa-induced dyskinesias (LIDs) are the most common and disabling adverse motor effect of therap...
Background Levodopa is the most efficacious drug in the symptomatic therapy of motor symptoms in Pa...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of lev...
The pathophysiology of levodopa-induced dyskinesias (LID) in Parkinson’s disease is not well underst...
We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocki...
Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic...
Background: In Parkinson’s disease (PD), the onset of levodopa-induced dyskinesias (LIDs) is difficu...
Levodopa-induced dyskinesias (LIDs) occur in the majority of patients with Parkinson's disease (PD) ...
The pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease is incompletely understoo...
[Purpose] To determine whether the development of levodopa-induced dyskinesia (LID) in Parkinson dis...
Objective: To investigate whether the magnitude of presynaptic dopamine depletion is a risk factor f...
We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or ab...
Levodopa-induced dyskinesia (LID), a long-term motor complication in Parkinson's disease (PD), is at...
Background and aims Serotonergic terminals play an important role in levodopa-induced dyskinesias (L...
Levodopa-induced dyskinesias (LIDs) are the most common and disabling adverse motor effect of therap...
Background Levodopa is the most efficacious drug in the symptomatic therapy of motor symptoms in Pa...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of lev...
The pathophysiology of levodopa-induced dyskinesias (LID) in Parkinson’s disease is not well underst...
We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocki...
Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic...